AbbVie, J&J, and Pfizer are all reliable income plays in this choppy market.

Analysis of nearly 68,000 patients finds biosimilar adoption increased following formulary changes; however, more than 1 in 7 patients switch back to HumiraBELLEVUE, Wash., June 29, 2026 (GLOBE ...

Seeking to replace blockbuster drugs that will soon lose patent protection, drug-maker AbbVie purchased a biotech firm for ...

I hit the buy button on AbbVie (NYSE:ABBV | ABBV Price Prediction) again last week, and I will hit it again the next time June’s macro noise hands me a discount. While short-term traders chase ...

Apogee Therapeutics, which is developing a promising atopic dermatitis drug, saw its stock close nearly 47% higher on Monday.

For the 18 million people living with rheumatoid arthritis, disease management currently means a lifetime of injections-a ...

AbbVie's diverse sales base is ideal for a buy-and-hold stock, and the company has proven it can adapt as key patents, such as Humira, expired in 2023. AbbVie's dividend is still less than half of its ...

AbbVie will add Apogee’s IL-23 blocker to its current immunology stalwarts Skyrizi and Rinvoq, which have helped the pharma ride out the steep patent cliff left behind from mega-blockbuster drug ...

The biotech is advancing an anti-inflammatory drug that originated with vTv for inflammatory bowel diseases, leaning on a ...

While agents like AbbVie's Humira have transformed the treatment landscape, not all patients benefit equally from the drug.

Income investors keep coming back to the same playbook in choppy markets: own businesses that have raised their payouts every ...

Bob covers the money in health care, focusing on health insurance and hospitals. His stories delve into Medicare Advantage, opaque prescription drug benefits, and how much executives actually make. He ...